445 related articles for article (PubMed ID: 11227397)
1. Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.
Markham A; Adkins JC
Pharmacoeconomics; 2000 Dec; 18(6):591-608. PubMed ID: 11227397
[TBL] [Abstract][Full Text] [Related]
2. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2003; 21(13):951-89. PubMed ID: 12959627
[TBL] [Abstract][Full Text] [Related]
3. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
Markham A; Jarvis B
Drugs; 2000 Nov; 60(5):1207-33. PubMed ID: 11129128
[TBL] [Abstract][Full Text] [Related]
4. Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.
Pieters WR; Wilson KK; Smith HC; Tamminga JJ; Sondhi S
Treat Respir Med; 2005; 4(2):129-38. PubMed ID: 15813665
[TBL] [Abstract][Full Text] [Related]
5. Inhaled salmeterol/fluticasone propionate: a review of its use in asthma.
Reynolds NA; Lyseng-Williamson KA; Wiseman LR
Drugs; 2005; 65(12):1715-34. PubMed ID: 16060707
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.
Sheth K; Borker R; Emmett A; Rickard K; Dorinsky P
Pharmacoeconomics; 2002; 20(13):909-18. PubMed ID: 12381242
[TBL] [Abstract][Full Text] [Related]
7. Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma.
Juniper EF; Jenkins C; Price MJ; James MH
Am J Respir Med; 2002; 1(6):435-40. PubMed ID: 14720030
[TBL] [Abstract][Full Text] [Related]
8. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
Frois C; Wu EQ; Ray S; Colice GL
Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.
O'Connor RD; Nelson H; Borker R; Emmett A; Jhingran P; Rickard K; Dorinsky P
Pharmacoeconomics; 2004; 22(12):815-25. PubMed ID: 15294013
[TBL] [Abstract][Full Text] [Related]
10. Salmeterol/fluticasone propionate: a review of its use in asthma.
McKeage K; Keam SJ
Drugs; 2009; 69(13):1799-828. PubMed ID: 19719334
[TBL] [Abstract][Full Text] [Related]
11. Fluticasone versus salmeterol/low-dose fluticasone for long-term asthma control.
Heyneman CA; Crafts R; Holland J; Arnold AD
Ann Pharmacother; 2002 Dec; 36(12):1944-9. PubMed ID: 12452759
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.
Johansson G; Andreasson EB; Larsson PE; Vogelmeier CF
Pharmacoeconomics; 2006; 24(7):695-708. PubMed ID: 16802845
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.
Doull I; Price D; Thomas M; Hawkins N; Stamuli E; Tabberer M; Gosden T; Rudge H
Curr Med Res Opin; 2007 May; 23(5):1147-59. PubMed ID: 17519082
[TBL] [Abstract][Full Text] [Related]
14. Salmeterol/fluticasone propionate combination.
Spencer CM; Jarvis B
Drugs; 1999 Jun; 57(6):933-40; discussion 941-3. PubMed ID: 10400406
[TBL] [Abstract][Full Text] [Related]
15. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.
O'Connor RD; Patrick DL; Parasuraman B; Martin P; Goldman M
J Asthma; 2010 Mar; 47(2):217-23. PubMed ID: 20170333
[TBL] [Abstract][Full Text] [Related]
16. Salmeterol/fluticasone propionate combination product in asthma. An evaluation of its cost effectiveness vs fluticasone propionate.
Pharmacoeconomics; 1999; 16 Suppl 2():i-viii, 1-34. PubMed ID: 10724799
[No Abstract] [Full Text] [Related]
17. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
[TBL] [Abstract][Full Text] [Related]
18. Seretide: a pharmacoeconomic analysis.
Fritscher L; Chapman KR
J Med Econ; 2008; 11(3):555-70. PubMed ID: 19450105
[TBL] [Abstract][Full Text] [Related]
19. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial.
Kavuru M; Melamed J; Gross G; Laforce C; House K; Prillaman B; Baitinger L; Woodring A; Shah T
J Allergy Clin Immunol; 2000 Jun; 105(6 Pt 1):1108-16. PubMed ID: 10856143
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group.
Lundbäck B; Jenkins C; Price MJ; Thwaites RM
Respir Med; 2000 Jul; 94(7):724-32. PubMed ID: 10926346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
